Alerta

Novel Anti-HSV Antibody

Resumen de: US20260265348A1

Described is a (first) anti-HSV antibody or an antigen-binding fragment thereof binding to the glycoprotein B (gB) of HSV-1 and/or HSV-2, wherein said antibody comprises the complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, each comprising the sequences as defined in the claims, wherein said antibody or antigen-binding fragment has a low dissociation rate kdis of at most 5.0×10−4 s−1, preferably at most 1.0×10−4 s−1, at most 5.0×10−5 s−1, and most preferably at most 2.9×10−5 s−1. Moreover, described is a combination of (A) said (first) anti-HSV antibody or an antigen-binding fragment thereof; and (B) a second anti-HSV antibody or an antigen-binding fragment thereof recognizing/binding to the glycoprotein B (gB) of the HSV-1 and/or HSV-2, wherein said antibody comprises the complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, each comprising the sequences as defined in the claims, wherein said second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Further, described is a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or the antigen-binding fragment thereof or the combination of said antibodies and at least one pharmaceutically acceptable excipient. Further, described is an anti-HSV antibody or the antigen-binding fragment t

TREG THERAPY

Resumen de: US20260263556A1

The present invention relates to a lipid nanoparticle comprising mRNA encoding FOXP3 and at least a second polypeptide, wherein said lipid nanoparticle comprises a moiety capable of specifically binding to a molecule expressed on a CD4+ T cell and wherein said mRNA is modified to have increased stability as compared to unmodified mRNA.

EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON ADMINISTRATION, AND USES

Resumen de: EP4803075A1

0001 Provided are compositions and drug delivery systems containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo. The MEVs are formulated and administered by a variety of routes of administration and have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as therapeutics for psychiatric diseases, disorders, and conditions as diagnostics, and other such uses.

NANOPARTICLE VACCINE FOR PREVENTING MYCOBACTERIUM TUBERCULOSIS INFECTION AND PREPARATION METHOD THEREFOR

Resumen de: EP4803097A1

0001 Disclosed is a Mycobacterium tuberculosis vaccine. Specifically, the vaccine comprises an immune composition comprising an antigen component and a particulate protein component. The particulate protein component comprises nanoparticle protein. The antigen component and the particulate protein component are covalently bound by means of a binding peptide 1 and a binding peptide 2 to form an immunogenic complex. The vaccine has excellent cell immunogenicity and antibody immunogenicity. The present invention also relates to a preparation method for the mycobacterium tuberculosis vaccine.

THERAPEUTIC AGENT FOR METABOLIC DISEASES COMPRISING DELIVERY SYSTEM BASED ON METAL NANOPARTICLE-NUCLEIC ACID CONJUGATE

Resumen de: EP4803104A1

0001 The present invention relates to a use, as a drug delivery vehicle, of a gene carrier comprising a metal nanoparticle and a double-stranded nucleic acid molecule bound to a surface of the metal nanoparticle, in particular to a use of the carrier for the treatment of a metabolic disease, and to a pharmaceutical composition for the prevention or treatment of a metabolic disease comprising the same.

METHOD FOR PREPARING STABLE PEPTIDE NANOPARTICLE FORMULATIONS

Resumen de: WO2025096329A1

The present disclosure is directed to methods of preparing peptide nanoparticle formulations, and in particular, peptide nanosuspensions, using low shear milling. More specifically, the disclosure is directed to methods of preparing peptide nanosuspensions by applying low frequency acoustic energy to an admixture comprising a peptide, an aqueous dispersion medium comprising a surface-active polymer and optionally a surfactant, and milling media, until the peptide has been milled to nanoparticle size. Also described are stable peptide nanosuspensions prepared by the methods.

PH-CONTROLLED BIODEGRADABLE POLYMERIC PARTICLES FOR SUSTAINED RELEASE OF POSITIVELY CHARGED SPECIES

Resumen de: WO2025096848A1

The disclosure relates to microparticles and nanoparticles comprising a porous polymer matrix comprising an uncapped polymer for sustained delivery of a net positively charged therapeutic agent. More particularly the disclosure relates to particles comprising PLGA or PLA which have a first state with relatively more interconnected pores at a first pH and a second state with relatively less interconnected pores at a second pH. Methods of making the particles and administering the particles are also provided.

RNA-SN-38 CONJUGATE FOR THE TREATMENT OF COLORECTAL CANCER AND SEQUENTIAL LUNG METASTASIS

Resumen de: WO2025097049A1

Disclosed herein are compositions and methods for CMC production of RNA therapeutic complexes (nanostructures) that contain SN-38 (7-Ethyl-10-hydroxycamptothecin) and/or Irinotecan. In particular, disclosed herein is an RNA nanoparticle having at least three synthetic RNA nucleotides coupled to each other, wherein the at least three synthetic RNA oligonucleotides form a central ore domain and at least three double-stranded arms arranged around the core domain and extending away from the central core domain, wherein at least one of the three double-stranded arms is conjugated with Irinotecan and/or SN-38 with an esterbond that is cleavable by esterase in cancer tissue or cancer cells.

TARGETED LNP DELIVERY

Resumen de: WO2025096824A1

Disclosed are lipid nanoparticle (LNP) delivery systems that specifically target T cells. The LNP delivery system comprises antibodies conjugated to the surface of the LNP, e.g., via maleimide chemistry, that target at least two T cell surface proteins, e.g., CD3 and CD28. The LNP delivery system can have a single population of LNP conjugated to either a bispecific antiCD3/antiCD28 antibody, or two monospecific antiCD3 and antiCD28 antibodies, or two populations of LNP wherein each population comprises a monospecific antibody. The payload of the LNP delivery system can be, e.g., mRNA encoding chimeric antigen receptors (CAR), a linear DNA fragment or a plasmid encoding chimeric antigen receptors (CAR) or therapeutic proteins such as antibodies, components of a gene editing systems (e.g., CRISPR-Cas), small molecules, antibody-drug conjugates (ADC), and any combination thereof, either encapsulated in the LNP or attached to its surface (e.g., conjugated). Also provided are lipids, pharmaceutical compositions, kits, and methods of treatment.

MULTIVALENT INFLUENZA MRNA VACCINE

Resumen de: EP4803629A1

0001 Provided is an isolated mRNA molecule, including a nucleotide sequence encoding a chimeric immunogenic polypeptide, where the chimeric immunogenic polypeptide includes an immunogenic fragment of hemagglutinin HA of influenza A H5N1, an immunogenic fragment of hemagglutinin HA of influenza A H1N1, and an immunogenic fragment of hemagglutinin HA of influenza B Victoria linked together. Further provided are a composition and a vaccine including the mRNA, a fusion protein encoded by the mRNA, and a method for inducing an immune response against an influenza virus in a subject using the mRNA, the composition, the vaccine, and the fusion protein.

IMMUNOGENIC COMPOSITION OF AFRICAN SWINE FEVER VIRUS CD2V PROTEIN AND USE THEREOF

Resumen de: EP4803532A1

An immunogenic fragment of African swine fever virus CD2V protein, a recombinant protein, an immunogenic composition, and a use thereof. The provided immunogenic fragment of African swine fever virus CD2V protein or a variant thereof with immunogenicity can greatly improve the expression quantity while retaining the strong immunocompetence.

COMPOSITIONS TARGETING KLKB1 AND METHODS OF USE THEREOF

Resumen de: WO2025096980A1

Disclosed are methods and compositions for functional genetic modifications at selected genomic sites such as KLKB1 gene. Also provided are cell populations, which comprise the functional genetic modification at one or more selected gene loci.

GLYCOENGINEERED EXTRACELLULAR VESICLES, METHODS OF PRODUCTION AND USES THEREOF

Resumen de: WO2025093745A1

The present invention relates to glycoengineered extracellular vesicles, as well as methods of production of such glycoengineered extracellular vesicles, methods of glycoengineering extracellular vesicles, and uses of glycoengineered extracellular vesicles.

LIPIDS AND LIPID NANOPARTICLE FORMULATIONS

Resumen de: WO2025091377A1

The present disclosure relates generally to lipids, lipid nanoparticle formulations, and methods of using the same for delivering nucleic acids, such as mRNA.

RNA FOR IN VIVO TRANSFECTION WITH INCREASED EXPRESSION

Resumen de: US20250144234A1

0000 This disclosure provides improved RNA molecules, including mRNA molecules that can be produced by in vitro transcription and are suitable for in vivo transfection using an appropriate delivery vehicle, such as a lipid nanoparticle (LNP) or targeted lipid nanoparticle (tLNP). The improved RNA include particular combinations of 5′ untranslated region (UTR) and 3′ UTR, particular 3′ UTRs, or particular open reading frame sequences. Also provided herein are compositions of the LNP, or tLNP with an antibody as a targeting moiety, such as anti-CD8 antibodies that are used as targeting moiety.

LIPID COMPOUNDS

Resumen de: WO2025096940A1

The present invention relates to lipids that include novel triazole, and alkyl- and alkene-substituted amine compounds, intermediates in their synthesis, and uses of such triazole, and alkyl- and alkene-substituted amine compounds in, for example, lipid nanoparticle compositions for drug delivery and cancer treatments.

PARTICLES, COMPOSITIONS AND METHODS

Resumen de: WO2025093665A1

The present disclosure relates generally to functionalized particles containing moieties capable of binding Immunoglobulin D (IgD), methods for producing them, and to pharmaceutical compositions containing them and their uses in medicine.

NOVEL GENE DELIVERY AGENTS

Resumen de: US20250144233A1

0000 Nanoparticle compositions for delivery of nucleic acids to subjects including aminoalkyl branched lipid-like molecules as carriers, and therapeutic or immunogenic nucleic acid agents enclosed within the nanoparticle containing are described. Also provided are methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects.

3'-UTR WITH IMPROVED TRANSLATION EFFICIENCY, A SYNTHETIC NUCLEIC ACID MOLECULE COMPRISING THE SAME, AND A VACCINE OR THERAPEUTIC COMPOSITION COMPRISING THE SAME

Resumen de: WO2025095526A1

The present invention relates to a synthetic nucleic acid molecule comprising 3'-UTR polynucleotide with improved translation efficiency and a vaccine composition comprising the same, and more particularly to a synthetic nucleic acid molecule comprising 3'-UTR with improved translation efficiency manufactured by inclusion of specific motif and a codon-optimized signal sequence and an antigen encoding sequence, and a vaccine composition comprising the same. The synthetic nucleic acid molecule according to the present invention comprises a 3'-UTR polynucleotide with improved translation efficiency, which can effectively induce the expression of an antigenic polypeptide, which is useful for vaccine development because it can be expected to increase immunogenicity as a vaccine.

SYNTHESIS AND APPLICATION OF MAGNETIC PARTICLE CONJUGATES FOR THE EXTRACORPOREAL REMOVAL OF ANTIBODIES TARGETING VIRAL VECTORS TO FACILITATE GENE THERAPY

Resumen de: WO2025215034A1

The present invention provides novel conjugates comprising a magnetic particle and a multitude of viral structures covalently bound to said particle. These conjugates are suited for efficient extracorporeal removal of antibodies from blood. In particular, the conjugates are suited as adjuvant treatment in gene therapy.

一种可电离阳离子脂质化合物及其制备方法和应用

Resumen de: CN117986153A

The invention provides an ionizable cationic lipid compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ionizable cationic lipid compound provided by the invention is a compound with a formula (1), or a salt, a stereoisomer and a tautomer thereof, can be used as a surfactant in various fields, and especially can be used as a lipid composition for delivering a therapeutic agent. The prepared lipid nanoparticles can show good effectiveness and safety in cells and in animal bodies. # imgabs0 #

用于递送的五组分脂质纳米颗粒

Resumen de: CN122701683A

本申请公开了一种脂质纳米颗粒，其包含式(I)所示化合物、阳离子脂质、磷脂、结构脂质和PEG脂质。本申请脂质纳米颗粒相较于传统的四组分脂质纳米颗粒可以更高效地将活性成分递送至细胞内，发挥治疗或预防目的。(I)

一种靶向modABC调控铁代谢的联合抗菌剂及其制备方法

Resumen de: CN122701876A

本申请公开了一种靶向modABC调控铁代谢的联合抗菌剂及其制备方法，属于抗感染药物技术领域。该联合抗菌剂中铁螯合剂与modABC通路抑制剂的质量比为1:0.5‑2，通过铁螯合剂与modABC通路抑制剂的协同作用，双重阻断细菌铁摄取途径，避免细菌产生代偿性铁摄取机制，实现高效杀菌；同时本申请提供联合抗菌剂的制备方法包括原料预处理、分散体系制备、乳化反应、载体成型、纯化处理、制剂后处理六个核心步骤，可根据实际制备需求，选择合适的分散介质、乳化参数、载体成型方法及功能辅料，实现联合抗菌剂的高效制备。

一种用于治疗和改善日光性皮炎的汉黄芩素立方液晶纳米粒水凝胶的制备方法及其应用

Resumen de: CN122701648A

本发明公开了一种用于治疗和改善日光性皮炎的汉黄芩素立方液晶纳米粒水凝胶的制备及其应用。本发明制备方法是先将汉黄芩素与GMO和F127制备成汉黄芩素立方液晶纳米粒，再加入羟苯甲酯、甘油、壳聚糖和乳酸制备成汉黄芩素立方液晶纳米粒水凝胶。该汉黄芩素立方液晶纳米粒水凝胶可用于治疗和改善日光性皮炎，且起效更快，外透皮能力强，能提供更久的药物渗透能力。

白藜芦醇-单形拟杆菌共封装微胶囊组合物、制备方法及其应用

Nº publicación: CN122701682A 08/09/2026

Solicitante:

北京市农林科学院

Resumen de: CN122701682A

本发明公开了一种白藜芦醇‑单形拟杆菌共封装微胶囊组合物、制备方法及其应用。属于微胶囊技术领域。针对疏水性多酚白藜芦醇稳定性差、单形拟杆菌在加工和消化道中易失活，以及现有技术难以将二者同步保护与递送的问题，本发明提供了一种以乳清分离蛋白、壳聚糖和果胶为壁材的多层复合微胶囊。该微胶囊利用乳清分离蛋白的疏水结构域包埋白藜芦醇形成蛋白核心，再依次包覆壳聚糖阳离子层和果胶外壳层，并将单形拟杆菌包埋于外层多糖屏障中。通过选择不同酯化度的果胶可调控外壳致密程度，实现胃液保护与肠液释放的平衡。本发明能够显著提高白藜芦醇的稳定性以及单形拟杆菌在包埋、贮藏、热处理和模拟胃液中的存活率。